Marshall Wace’s Avita Medical RCEL Stock Holding History

Marshall Wace’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.4M	Buy	338,387 +285,825	+544%	+$1.23M	﹤0.01%	2043
2026 Q1	$194K	Buy	+52,562	New	+$221K	﹤0.01%	2796
2025 Q4	–	Sell	-42,807	Closed	-$219K	–	3393
2025 Q3	$219K	Sell	42,807 -34,018	-44%	-$177K	﹤0.01%	2546
2025 Q2	$406K	Sell	76,825 -37,267	-33%	-$271K	﹤0.01%	2213
2025 Q1	$929K	Buy	+114,092	New	+$1.07M	﹤0.01%	1816
2023 Q4	–	Sell	-13,406	Closed	-$196K	–	2534
2023 Q3	$196K	Sell	13,406 -12,094	-47%	-$205K	﹤0.01%	1978
2023 Q2	$434K	Sell	25,500 -36,215	-59%	-$531K	﹤0.01%	2031
2023 Q1	$862K	Sell	61,715 -1,759	-3%	-$18.7K	﹤0.01%	1883
2022 Q4	$419K	Buy	63,474 +48,983	+338%	+$294K	﹤0.01%	2439
2022 Q3	$77K	Buy	+14,491	New	+$89.5K	﹤0.01%	3210
2021 Q3	–	Sell	-30,828	Closed	-$633K	–	3351
2021 Q2	$633K	Buy	+30,828	New	+$608K	﹤0.01%	2025

Other funds holding RCEL

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Marshall Wace's RCEL Position: Q2 2026 in Review

Marshall Wace increased its Avita Medical (RCEL) stake by 544% in Q2 2026, buying an estimated $1.23M and bringing the position to 338,387 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

Marshall Wace first reported a position in RCEL in Q2 2021 and has held it in 11 quarters since. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

Marshall Wace held 338,387 shares of Avita Medical worth $1.4M as of Q2 2026.
Marshall Wace bought 285,825 Avita Medical shares in Q2 2026, an estimated $1.23M.
Avita Medical made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2043 holding.
Marshall Wace first reported a position in Avita Medical in Q2 2021 and has held it in 11 quarters since.
73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.